Drugs Made In America Acquisiti vs Daedalus Special Acquisition Co — Valuation Comparison 2026
Access all valuation models for DMII vs DSAC — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →DSAC scores higher with a 4.7/10 quality rating vs DMII's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing Drugs Made In America Acquisiti (DMII) and Daedalus Special Acquisition Co (DSAC) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
DMII currently trades at $10.06 with a QOC of 4.6/10, while DSAC trades at $9.99 with a QOC of 4.7/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).